Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
John E. Levine(Icahn School of Medicine at Mount Sinai), James L.M. Ferrara(Tisch Hospital), Sung Won Choi(University of Michigan), Raymond J. Hutchinson(Children's Hospital of Los Angeles), Shin Mineishi(University of Alabama at Birmingham), Carrie L. Kitko(Vanderbilt University Medical Center), Pavan Reddy(Wichita State University), Gregory A. Yanik(University of Michigan), Thomas Braun(University of Michigan), Dawn Jones(University of Michigan), Oleg I. Krijanovski, Daniel Bickley(University of Michigan), Yasser Khaled(Methodist University Hospital), Sophie Paczesny(MUSC Hollings Cancer Center)
Cited by 190
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
|Frontiers in Immunology|2017|612
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
|New England Journal of Medicine|2018|598